+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07039110

Real-World Evaluation of Risankizumab on Quality of Life in Adults with Moderate-to-Severe Plaque Psoriasis

Led by AbbVie · Updated on 2026-10-01

700

Participants Needed

84

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Plaque psoriasis is a chronic inflammatory skin condition that causes thick, red, and scaly patches. This research evaluates how treatment with risankizumab affects the quality of life in adults with moderate to severe plaque psoriasis in real-world clinical settings. About 700 participants prescribed risankizumab by their doctors according to local guidelines will be involved in this study. Participants will receive risankizumab as directed by their physicians based on routine care and local labeling. There are no additional treatments or study drugs provided beyond what is normally prescribed. The study is observational and follows participants for up to 2.5 years while they continue their usual treatment. During the study, participants will attend regular visits at hospitals or clinics as part of their standard care. Researchers will assess outcomes such as the proportion of participants achieving a Dermatology Life Quality Index DLQI score of 0 or 1 at 12 months. The study aims to understand the impact of risankizumab on quality of life with minimal extra burden to participants.

CONDITIONS

Brief Title

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Research Team

J

Julieta Gonzalez Blanco

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here